Abstract iPSC lines derived from MDS and AML patient samples can map clonal evolution, disease progression and regression, and identify disease stage-specific medication effects.
This study used cell reprogramming and genetics to develop a panel of patient-derived, disease stagespecific iPSC lines that provides a phenotypic roadmap of myeloid disease progression and can be custom tailored through genome editing approaches. The small number of primary patient samples and inability of some cells with specific mutations to reprogram are limitations; overall, however, stage-specific iPSC lines represent a powerful new tool for functional studies of myeloid diseases, demonstrating proof of principle that treatment effects can be studied in these models with potentially broader cancer applicability.
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